C12N 2770/36034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/36034 (Use of virus or viral component as vaccine) appears on 10 US grants and 19 published applications in this corpus.
Search patents in C12N- Granted patents
- 10
- Published applications
- 19
- Assignees
- 15
- Inventors
- 35
- Latest grant
- 21 Jun 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 2 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 2 | 6 |
| 2019 | 2 | 3 |
| 2020 | 1 | 2 |
| 2021 | 3 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CHIKV RNA vaccines21 Jun 2022US 11,364,292 B2ModernaTX, Inc.
- DNA antibody constructs and method of using same28 Dec 2021US 11,208,470 B2Inovio Pharmaceuticals, Inc.
- Exosomes and their use as vaccine1 Jun 2021US 11,020,471 B2Fundació Institut D'Investigació En CiéNcies De La Salut Germans Trias | Pujol
- Infectious disease vaccines18 May 2021US 11,007,260 B2ModernaTX, Inc.
- CHIKV RNA vaccines7 Jul 2020US 10,702,597 B2ModernaTX, Inc.
- Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof15 Jan 2026US 2026/0015592 A1Ottawa Hospital Research Institute
- Or2l13 agonists to treat cvd with dysregulated platelet activation4 Apr 2024US 2024/0108591 A1The Cleveland Clinic Foundation
- Infectious disease vaccines19 Jan 2023US 2023/0020362 A1ModernaTX, Inc.
- DNA Antibody Constructs And Method Of Using Same14 Apr 2022US 2022/0112273 A1Inovio Pharmaceuticals, Inc.
- Zika virus mrna vaccines26 Nov 2020US 2020/0368343 A1ModernaTX, Inc.
Most cited
By later US patents
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019
- Malaria vaccine17US 9,512,190 B2VLP Thereapeutics, LLC · 2016
- Compositions and methods for generating a synthetic antibody4US 9,994,629 B2The Trustees of the University of Pennsylvania · 2018
- CHIKV RNA vaccines2US 11,364,292 B2ModernaTX, Inc. · 2022
- Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus2US 9,919,047 B2Sillajen Biotherapeutics, Inc. · 2018